Oratile Kgosidialwa1, Kieran Blake2, Oisin O'Connell2,3, Jim Egan2,3, Jim O'Neill2,4, Mensud Hatunic5,6. 1. Department of Endocrinology, Mater Misericordiae University Hospital, Dublin, Ireland. 2. School of Medicine, University College Dublin, Dublin, Ireland. 3. Department of Respiratory Medicine and Lung & Heart Transplantation, Mater Misericordiae University Hospital, Dublin, Ireland. 4. Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland. 5. Department of Endocrinology, Mater Misericordiae University Hospital, Dublin, Ireland. mhatunic@mater.ie. 6. School of Medicine, University College Dublin, Dublin, Ireland. mhatunic@mater.ie.
Abstract
BACKGROUND: The incidence of post-transplant diabetes (PTDM) is variable primarily due to a lack of standardised diagnostic criteria. AIM: This study aimed to assess the incidence of PTDM in heart and lung transplant (HLT) patients and to review if the management of these patients is in accordance with the 2014 American Society of Transplantation guidelines. METHODS: This was a retrospective study in the Mater Misericordiae University Hospital, Dublin, Ireland. Data was collected from the patients who had undergone HLT. RESULTS: All patients who had a heart and/or lung transplant between 2005 and 2017 were identified. The majority of our patients had lung 111 (53.9%), heart 94 (45.6%) and combined heart/lung 1(0.5%) transplants. A total of 174 (84.5%) patients were screened for diabetes pre-transplantation. Two hundred five (99.9%) patients were screened for PTDM post-surgery. The cumulative incidence for PTDM was 19.4% (40/206). All patients with PTDM were on prednisolone, 32 (80%) on tacrolimus and 4 (10%) on cyclosporine. CONCLUSIONS: The cumulative incidence of post-transplant diabetes in our cohort was 19.4%. The majority of the patients were screened before and after transplant for glucose abnormality. The authors recommend that all patients should be managed in a multidisciplinary setting including transplant physicians, endocrinlogist, diabetes nurse specialists, transplant nurses and dietitians.
BACKGROUND: The incidence of post-transplant diabetes (PTDM) is variable primarily due to a lack of standardised diagnostic criteria. AIM: This study aimed to assess the incidence of PTDM in heart and lung transplant (HLT) patients and to review if the management of these patients is in accordance with the 2014 American Society of Transplantation guidelines. METHODS: This was a retrospective study in the Mater Misericordiae University Hospital, Dublin, Ireland. Data was collected from the patients who had undergone HLT. RESULTS: All patients who had a heart and/or lung transplant between 2005 and 2017 were identified. The majority of our patients had lung 111 (53.9%), heart 94 (45.6%) and combined heart/lung 1(0.5%) transplants. A total of 174 (84.5%) patients were screened for diabetes pre-transplantation. Two hundred five (99.9%) patients were screened for PTDM post-surgery. The cumulative incidence for PTDM was 19.4% (40/206). All patients with PTDM were on prednisolone, 32 (80%) on tacrolimus and 4 (10%) on cyclosporine. CONCLUSIONS: The cumulative incidence of post-transplant diabetes in our cohort was 19.4%. The majority of the patients were screened before and after transplant for glucose abnormality. The authors recommend that all patients should be managed in a multidisciplinary setting including transplant physicians, endocrinlogist, diabetes nurse specialists, transplant nurses and dietitians.
Authors: Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz Journal: JAMA Date: 2014-02-05 Impact factor: 56.272
Authors: Manfred Hecking; Michael Haidinger; Dominik Döller; Johannes Werzowa; Andrea Tura; Jinyao Zhang; Hilal Tekoglu; Johannes Pleiner; Thomas Wrba; Susanne Rasoul-Rockenschaub; Ferdinand Mühlbacher; Sabine Schmaldienst; Wilfred Druml; Walter H Hörl; Michael Krebs; Michael Wolzt; Giovanni Pacini; Friedrich K Port; Marcus D Säemann Journal: J Am Soc Nephrol Date: 2012-02-16 Impact factor: 10.121
Authors: Fernando G Cosio; Yogish Kudva; Marije van der Velde; Timothy S Larson; Stephen C Textor; Matthew D Griffin; Mark D Stegall Journal: Kidney Int Date: 2005-06 Impact factor: 10.612
Authors: Thomas E Burroughs; Jason Swindle; Steven Takemoto; Krista L Lentine; Gerardo Machnicki; William D Irish; Daniel C Brennan; Mark A Schnitzler Journal: Transplantation Date: 2007-04-27 Impact factor: 4.939